课题基金 / 基金详情

Pharmacogenomics of Gastric Function & Weight in Obesity

Pharmacogenomics of Gastric Function & Weight in Obesity
胃功能的药物基因组学
批准号:
9098206
负责人:
MICHAEL L. CAMILLERI
金额:
$39.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-01 至 2016-11-30

项目摘要

项目成果

MICHAEL L. CAMILLERI的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(申请人提供):肥胖率在全球范围内持续上升;69%的美国成年人超重或肥胖。尽管在肥胖症的病理生理学方面取得了进展,但目前的非手术治疗(饮食、运动和药物治疗)的减肥效果是高度可变的,而且肥胖症药物疗法减肥的预测因素也是未知的。在DK67071资助的两项针对328名患者的研究中,肥胖与更大的空腹胃容量、更快的胃固体排空、更低的餐后峰值血浆PYY、更高的餐后峰值血浆GLP-1、更高的卡路里来实现饱腹感[体积到饱满度]和通过随意进餐唤起饱足感有关。在肥胖的易感基因中,解偶联蛋白(UCP)-3基因的变异(rs1626521,影响人类线粒体功能)与胃运动功能、饱腹感和饱腹感(15个候选基因的校正后显著相关)相关。我们的初步数据显示:(A)GLP-1激动剂延缓胃排空,减少随意餐的卡路里摄入量,在携带TCF7L2 rs7903146的T等位基因携带者中体重减轻显著;(B)临时卡路里摄入量 (C)回肠给药熊去氧胆酸(UDCA)降低了空腹和餐后血糖,并且一组患者有显著的餐后胰岛素反应,这与UDCA和TGR5基因变异之间的药物遗传相互作用的假说一致。我们建议检验总体假设,即基于数量性状和基因变异的特定异常,药物减肥可能是个体化的;每一种都可能被特定肥胖药物的药理作用所针对。我们在三种不同的肥胖表型中提出了具体的目标,评估了在超重或肥胖患者中,与安慰剂相比,数量性状和相关候选基因影响治疗反应的可能性:(A)GLP-1受体激动剂exenatide,在胃排空加速的患者中,特别是在TCF7L2 rs7903146(TT型)携带者中;(B)中枢作用的组合去甲肾上腺素能交感性胺,苯终端,以及抗惊厥药物托吡酯,在饱腹感降低(食欲增加)的患者中,特别是在UCP-3 rs1626521变异的携带者中,它控制线粒体功能和细胞能量;(C)回结肠递送UDCA,这是一种TGR5受体激活剂,在接受二甲双胍治疗的肥胖高血糖患者中,特别是在TGR-5 rs11554825基因变异的携带者中。将通过测量肥胖和正常体重个体之间不同的所有数量特征来探索替代策略:固体和液体的胃排空、空腹和餐后胃容量、饱腹感、饱腹感、餐后PYY和GLP-1,以及血糖指数(餐后血糖、胰岛素)。意义:我们的研究致力于肥胖症的治疗,引入了一个基于定量生物标志物和药物基因组学的肥胖症个体化药物治疗时代。因此,它解决了一个重要的公共卫生挑战。
英文摘要
 DESCRIPTION (provided by applicant): Obesity prevalence continues to increase worldwide; 69% of U.S. adults are overweight or obese. Despite advances in understanding obesity pathophysiology, weight loss with current non-surgical treatments (diet, exercise and medications) is highly variable, and predictors of weight loss with obesity pharmacotherapy are unknown. In two studies of 328 patients funded by DK67071, obesity was associated with greater fasting gastric volume, accelerated gastric emptying of solids, lower postprandial peak plasma PYY, higher postprandial peak plasma GLP-1, greater calories to achieve satiation [volume to fullness] and to evoke satiety with an ad-libitum meal.. Among candidate genes predisposing to obesity, variants in uncoupling protein (UCP)-3 gene (rs1626521, which influences human mitochondrial function) were associated with gastric motor function, satiation and satiety (significant with correction for testing 15 candidate genes). Our preliminary data shows (a) GLP-1 agonist delays gastric emptying, reduces calorie intake at ad-libitum meal, and weight loss is prominent in T allele carriers of TCF7L2 rs7903146; (b) calorie intake at ad-libitum meal predicted weight loss in response to phentermine-topiramate-ER; (c) ileocolonic delivery ursodeoxycholic acid (UDCA) reduced fasting and postprandial blood glucose, and a subgroup of patients had a marked postprandial insulin response consistent with the hypothesis of pharmacogenetic interaction between UDCA and TGR5 gene variation. We propose to test the overall hypothesis that weight loss with pharmacological agents may be individualized, based on specific abnormalities in quantitative traits, and genotype variation; each could be targeted by pharmacological actions of specific obesity medications. We propose specific aims in three different obesity phenotypes, assessing the potential for a quantitative trait and a related candidate gene to impact the response to treatment compared to placebo among overweight or obese patients: (a) the GLP-1 receptor agonist, exenatide, in those with accelerated gastric emptying, particularly in carriers of TCF7L2 rs7903146 (TT genotype); (b) the centrally acting combination noradrenergic sympathomimetic amine, phentermine, and anticonvulsant, topiramate, in those with reduced satiety (increased appetite), particularly in carriers of variant of UCP-3 rs1626521 genotype, which controls mitochondrial function and cellular energetics; (c) the ileo- colonic delivered UDCA, an activator of TGR5 receptors in obese patients with hyperglycemia treated with metformin, particularly in carriers of variants of TGR-5 rs11554825 genotype. Alternative strategies will be explored through measurements of all quantitative traits that differ between obese and normal weight individuals: gastric emptying of solids and liquids, fasting and postprandial gastric volume, satiation, satiety, postprandial PYY and GLP-1, and glycemic indices (postprandial glucose, insulin). Significance: Our study addresses the treatment of obesity, introducing an era of individualizing drug therapy for obesity based on quantitative biomarkers and pharmacogenomics. Therefore, it addresses an important public health challenge.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1111/nmo.12823
发表时间: 2016-08-01
期刊: NEUROGASTROENTEROLOGY AND MOTILITY
影响因子: 3.5
作者: [Camilleri, M.]
通讯作者: Camilleri, M.
A randomized control trial of G-POEM for gastroparesis to assess feasibility, safety, efficacy and physiological mechanisms
  • 批准号:
    10843438
  • 项目类别:
  • 资助金额:
    $51.07万
  • 财政年份:
    2023
  • 负责人:
    MICHAEL L. CAMILLERI
  • 依托单位:
Parkinson Disease Neural Circuitry and Gastrointestinal Pathobiology
  • 批准号:
    10740119
  • 项目类别:
  • 资助金额:
    $58.43万
  • 财政年份:
    2023
  • 负责人:
    MICHAEL L. CAMILLERI
  • 依托单位:
Effect of VNS on Gastric Motor Functions
  • 批准号:
    10610561
  • 项目类别:
  • 资助金额:
    $7.58万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL L. CAMILLERI
  • 依托单位:
Effect of VNS on Gastric Motor Functions
  • 批准号:
    10709641
  • 项目类别:
  • 资助金额:
    $7.58万
  • 财政年份:
    2022
  • 负责人:
    MICHAEL L. CAMILLERI
  • 依托单位:
海外基金